Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
Many monoclonal antibodies (mAbs) have been extensively used in the clinic, such as rituximab to treat lymphoma. However, resistance and non-responsiveness to mAb treatment have been challenging for this line of therapy. Complement is one of the main mediators of antibody-based cancer therapy via the complement-dependent cytolysis (CDC) effect. CD59 plays a critical role in resistance to mAbs through the CDC effect. In this paper, we attempted to investigate whether the novel CD59 inhibitor, recombinant ILYd4, was effective in enhancing the rituximab-mediated CDC effect on rituximab-sensitive RL-7 lymphoma cells and rituximab-induced resistant RR51.2 cells. Meanwhile, the CDC effects, which were mediated by rituximab and anti-CD24 mAb, on the refractory multiple myeloma (MM) cell line ARH-77 and the solid tumor osteosarcoma cell line Saos-2, were respectively investigated. We found that rILYd4 rendered the refractory cells sensitive to the mAb-mediated CDC effect and that rILYd4 exhibited a synergistic effect with the mAb that resulted in tumor cells lysis. This effect on tumor cell lysis was apparent on both hematological tumors and solid tumors. Therefore, rILYd4 may serve as an adjuvant for mAb mediated-tumor immunotherapy.
Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Tao
T
You
Weiguo
W
Hu
Xiaowen
X
Ge
Jingnan
J
Shen
Xuebin
X
Qin
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology; D001430:Bacteriocins / Q000737:chemistry / Q000494:pharmacology; D051927:CD24 Antigen / Q000276:immunology; D018957:CD59 Antigens / Q000378:metabolism*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003165:Complement System Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008223:Lymphoma / Q000276:immunology / Q000473:pathology; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology*; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000494:pharmacology*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001430:Bacteriocins; D051927:CD24 Antigen; D018957:CD59 Antigens; D011994:Recombinant Proteins; C403910:intermedilysin protein, Streptococcus intermedius; C051590:CD59 protein, human; D000069283:Rituximab; D003165:Complement System Proteins
J Immunol. 2010 Jan 1;184(1):359-68
19955519
Blood. 2000 Jun 15;95(12):3900-8
10845926
Expert Opin Investig Drugs. 2009 Apr;18(4):491-500
19335277
J Exp Med. 1997 Feb 3;185(3):507-16
9053451
Int J Cancer. 1997 Jun 11;71(6):1049-55
9185710
Oncol Rep. 2009 Jun;21(6):1405-11
19424617
Cancer Treat Res. 2009;152:447-57
20213407
J Hematol Oncol. 2009 Jul 20;2:29
19619273
Cancer Res. 2007 Nov 1;67(21):10556-63
17975000
Leuk Res. 2006 May;30(5):625-31
16289746
Scand J Immunol. 2006 May;63(5):355-64
16640659
Nat Struct Mol Biol. 2004 Dec;11(12):1173-8
15543155
Blood. 2008 Jun 15;111(12):5486-95
18390837
Semin Oncol. 2000 Oct;27(5):598-613
11049026
Biochemistry. 1996 Mar 12;35(10):3263-9
8605162
Clin Ter. 2000 May-Jun;151(3):187-93
10958054
Infect Immun. 2005 Oct;73(10):6199-209
16177291
Cancer. 2006 Mar 1;106(5):1154-61
16421923
Acta Crystallogr D Biol Crystallogr. 2007 Jun;63(Pt 6):714-21
17505110
Cancer Res. 2008 Jul 15;68(14):5979-87
18632654
Clin Cancer Res. 2009 Feb 1;15(3):851-7
19188155
Int J Cancer. 1997 Jan 6;70(1):14-25
8985085
Semin Oncol. 2000 Dec;27(6 Suppl 12):79-85
11226004
J Biol Chem. 1998 Apr 24;273(17):10665-71
9553129
Mol Immunol. 2009 Apr;46(7):1561-7
19200600
J Biol Chem. 2006 Sep 15;281(37):27398-404
16844690
Oncogene. 2007 May 28;26(25):3629-36
17530016
Mol Immunol. 2007 Sep;44(16):3823-37
17768100
J Surg Oncol. 1997 Mar;64(3):222-30
9121154
Nat Med. 2008 Jan;14(1):98-103
18157141
Cell Mol Immunol. 2010 Sep;7(5):334-40
20228834
J Biol Chem. 2009 May 8;284(19):12719-26
19293153
Semin Oncol. 2003 Aug;30(4):424-33
12939711
Mol Immunol. 2003 Sep;40(2-4):109-23
12914817
Br J Haematol. 2008 Apr;141(2):135-48
18318769
Curr Oncol Rep. 2009 Jul;11(4):307-13
19508836
Scand J Immunol. 2000 Jun;51(6):634-41
10849376
Oncologist. 2008 Sep;13(9):954-66
18779537
Cell Mol Immunol. 2009 Feb;6(1):61-6
19254481
J Cell Physiol. 2000 Dec;185(3):317-23
11056001
J Immunother. 2001 May-Jun;24(3):263-71
11394505
Blood. 2001 Dec 1;98(12):3383-9
11719378
Eur J Immunol. 2005 Jul;35(7):2175-83
15971270